Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant cetuximab + cisplatin + gemcitabine in resectable stage IB–IIIA NSCLC
2004-002536-26Phase 2Completed
- Sponsor
- Dr Ken O'Byrne
- Start
- Sep 2004
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab in non-small cell lung cancer (NSCLC), sponsored by Dr Ken O'Byrne. Primary endpoints: Confirmed radiological response to treatment, Complete pathological response rate and 1 more. Started Sep 2004; status: completed.
02
Drugs
cetuximab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2004-002536-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002536-26.